0001104659-24-060529.txt : 20240513 0001104659-24-060529.hdr.sgml : 20240513 20240513161044 ACCESSION NUMBER: 0001104659-24-060529 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240513 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240513 DATE AS OF CHANGE: 20240513 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Cara Therapeutics, Inc. CENTRAL INDEX KEY: 0001346830 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36279 FILM NUMBER: 24939156 BUSINESS ADDRESS: STREET 1: 400 ATLANTIC STREET, SUITE 500 CITY: STAMFORD STATE: CT ZIP: 06901 BUSINESS PHONE: 203-406-3700 MAIL ADDRESS: STREET 1: 400 ATLANTIC STREET, SUITE 500 CITY: STAMFORD STATE: CT ZIP: 06901 FORMER COMPANY: FORMER CONFORMED NAME: Cara Therapeutics Inc DATE OF NAME CHANGE: 20051213 8-K 1 tm2414193d1_8k.htm FORM 8-K
false 0001346830 0001346830 2024-05-13 2024-05-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported) May 13, 2024

  

CARA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-36279   75-3175693

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

         

400 Atlantic Street

Suite 500

Stamford, Connecticut

       06901
(Address of principal executive offices)       (Zip Code)
         
Registrant's telephone number, including area code (203) 406-3700

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):

  

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol Name of each exchange on which registered
Common Stock, par value $0.001 per share CARA The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨.

 

 

 

 

 

Item 2.02. Results of Operations and Financial Condition.

 

On May 13, 2024, Cara Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2024. A copy of the press release is being furnished to the Securities and Exchange Commission as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference to this Item 2.02.

 

The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any of the Company’s filings with the Securities and Exchange Commission under the Exchange Act or the Securities Act of 1933, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such a filing.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits  

 

Exhibit No. Description
   
99.1 Press Release dated May 13, 2024
104 Cover page interactive data file (formatted as Inline XBRL)

 

2 

 

 

SIGNATURES 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  CARA THERAPEUTICS, INC.  
   
  By: /s/ RYAN MAYNARD
    Ryan Maynard
    Chief Financial Officer
    (Principal Financial and Accounting Officer)

 

Date: May 13, 2024

 

3 

 

 EX-99.1 2 tm2414193d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1 

 

 

 

Cara Therapeutics Reports First Quarter 2024 Financial Results

 

– Topline efficacy and safety results from KOURAGE 1 Part A portion of notalgia paresthetica (NP) pivotal program now expected by the end of 2Q24 –

 

STAMFORD, Conn., May 13, 2024 – Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced financial results and operational highlights for the first quarter ended March 31, 2024.

 

“Our notalgia paresthetica (NP) pivotal clinical program is progressing ahead of schedule and we now expect to report topline efficacy and safety results from KOURAGE 1 Part A by the end of the second quarter of 2024,” said Christopher Posner, President and Chief Executive Officer of Cara Therapeutics. “We believe the medical dermatology community’s interest in our clinical program underscores the significant unmet need for an effective and safe anti-pruritic treatment for the sizeable NP patient population. We look forward to rapidly advancing the ongoing Phase 2/3 program of our differentiated asset, oral difelikefalin, in this common but under-explored sensory neuropathy.”

 

KOURAGE Update

 

KOURAGE 1 Part A is the dose-finding portion of the Phase 2/3 clinical program evaluating oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with NP. The Company enrolled 214 patients and expects topline efficacy and safety results from KOURAGE 1 Part A by the end of the second quarter of 2024. Part A is not powered for statistical significance. This readout will provide key information, specifically the dose and sample size to initiate the Phase 3 pivotal portion of the program – Part B of KOURAGE 1 and the second study KOURAGE 2. Final topline results from the first pivotal study are expected by the end of 2025 with the second pivotal study results in early 2026.

 

In March 2024, the Company hosted a virtual event, Meet the NP Experts, featuring a panel of leading dermatologists and key opinion leaders to discuss the unmet need in NP and the potential of oral difelikefalin. A replay of the webcast is available under “Events & Presentations” in the Investors section of the Company’s website, www.CaraTherapeutics.com.

 

1Q24 KORSUVA Injection U.S. Update

 

In the first quarter of 2024, KORSUVA® (difelikefalin) injection generated net sales of approximately $1.8 million and the Company recorded collaborative revenue of approximately $800,000, which represented the Company’s share of the profit from sales of KORSUVA injection.

 

 

 

 

 

 

Wholesalers shipped 111,720 vials to dialysis centers during the first quarter of 2024.

 

On March 31, 2024, the Transitional Drug Add-On Payment Adjustment (TDAPA) period for KORSUVA injection expired. After the TDAPA period, KORSUVA injection is reimbursed through the ESRD PPS bundle.

 

First Quarter 2024 Financial Results

 

Cash, cash equivalents and marketable securities at March 31, 2024 totaled $69.8 million compared to $100.8 million at December 31, 2023. The decrease in the balance primarily resulted from $30.5 million of cash used in operating activities.

 

For the first quarter of 2024, net loss was $30.7 million, or $(0.56) per basic and diluted share, compared to net loss of $26.7 million, or ($0.49) per basic and diluted share, for the same period in 2023.

 

Revenues: Total revenue was $2.1 million and $6.2 million for the three months ended March 31, 2024 and 2023, respectively. Revenue primarily consisted of:

 

·$0.8 million and $2.8 million of collaborative revenue related to our share of the profit from CSL Vifor’s sales of KORSUVA injection to third parties during the three months ended March 31, 2024 and 2023, respectively.

 

·$0.6 million and $3.2 million of commercial supply revenue related to sales of KORSUVA injection to CSL Vifor during the three months ended March 31, 2024 and 2023, respectively.

 

·$0.6 million of other revenue related to royalty payments earned in conjunction with ex U.S. sales of KORSUVA/Kapruvia under agreements with CSL Vifor and Maruishi Pharmaceuticals Co. Ltd., or Maruishi, during the three months ended March 31, 2024, which were sold under the Purchase and Sale agreement with HCRX Investments Holdco, L.P. and Healthcare Royalty Partners IV, L.P., or the HCR Agreement, and considered non-cash. There was no other revenue during the three months ended March 31, 2023.

 

Cost of Goods Sold: Cost of goods sold was $0.6 million and $2.6 million for the three months ended March 31, 2024 and 2023, respectively, related to commercial supply revenue for KORSUVA injection sales to CSL Vifor.

 

Research and Development (R&D) Expenses: R&D expenses were $22.0 million for the three months ended March 31, 2024 compared to $24.3 million in the same period of 2023. The lower R&D expenses in 2024 were primarily due to decreases in stock-based compensation expense, payroll and related costs, travel costs and other related conference costs as well as lower costs associated with the discontinuation of our atopic dermatitis and advanced chronic kidney disease programs, partially offset by increases related to the oral difelikefalin NP program.

 

 

 

 

 

 

General and Administrative (G&A) Expenses: G&A expenses were essentially flat at $6.8 million for the three months ended March 31, 2024 compared to $6.9 million in the same period of 2023.

 

Restructuring Expenses: Restructuring expenses were $2.4 million for the three months ended March 31, 2024 which were related to our strategic prioritization of NP and the associated workforce reduction in the 2024 period. There were no restructuring expenses recorded during the three months ended March 31, 2023.

 

Other Income, net: Other income, net was approximately $1.0 million for each of the three months ended March 31, 2024 and 2023.

 

Non-cash interest expense on liability related to sales of future royalties and milestones: Non-cash interest expense was $2.0 million which represented imputed interest on the carrying value of the liability associated with the HCR Agreement and the amortization of the related issuance costs associated with the HCR Agreement for the three months ended March 31, 2024. There was no non-cash interest expense for the three months ended March 31, 2023.

 

Financial Guidance

 

Cara expects that our current unrestricted cash and cash equivalents and available-for-sale marketable securities will be sufficient to fund our currently anticipated operating plan into 2026. Our current operating plan assumes certain costs related to our planned pivotal trials in NP.

 

About the KOURAGE Phase 2/3 Clinical Program in Notalgia Paresthetica

 

KOURAGE is a Phase 2/3 clinical program evaluating oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica (NP). The program is comprised of two studies – KOURAGE 1 and KOURAGE 2 – which will likely be double-blind, placebo-controlled, 8-week studies with patients allowed to roll-over into open-label 52-week extensions.

 

KOURAGE 1 is composed of two parts. The dose-finding portion of KOURAGE 1 (Part A) includes 214 patients who are randomized equally to four arms (0.25 mg BID, 1.0 mg BID, 2.0 mg BID, placebo BID). Part A is not powered for statistical significance.

 

Part B and KOURAGE 2 will likely be double-blind, placebo-controlled, 8-week studies with patients randomized 1:1 to either difelikefalin or matching placebo. The primary endpoint for both the dose-finding portion of KOURAGE 1 (Part A) and the two pivotal studies Part B and KOURAGE 2 will likely be the proportion of patients with a ≥4-point improvement at Week 8 from baseline in the worst itch numeric rating scale.

 

 

 

 

 

 

About Cara Therapeutics

 

Cara Therapeutics is a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company is developing an oral formulation of difelikefalin, a selective, peripherally acting, non-scheduled kappa opioid receptor agonist, for the treatment of chronic pruritus associated with notalgia paresthetica (NP), a common, underdiagnosed neuropathy affecting the upper back for which there are no FDA-approved therapies. The Company is conducting a Phase 2/3 clinical program in NP with topline results of the dose-finding portion expected by the end of the second quarter of 2024. Cara Therapeutics also developed an IV formulation of difelikefalin, which is approved in the United States, EU, and multiple other countries for the treatment of moderate-to-severe pruritus associated with advanced chronic kidney disease in adults undergoing hemodialysis. The IV formulation is out-licensed worldwide. For more information, visit www.CaraTherapeutics.com and follow the company on X (Twitter), LinkedIn and Instagram.

 

Forward-looking Statements

 

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Examples of these forward-looking statements include statements concerning the Company’s planned future regulatory submissions and potential future regulatory approvals, future product launches, expected timing of the initiation, enrollment and data readouts from the Company’s planned and ongoing clinical trials, the potential results of ongoing clinical trials, timing of future regulatory and development milestones for the Company’s product candidate, the potential for the Company’s product candidate to be an alternative in the therapeutic areas investigated, including notalgia paresthetica, the size and growth of the potential markets for pruritus management such as notalgia paresthetica, the commercial potential of the Company’s product candidate, and the Company’s cash runway. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. The risks are described more fully in Cara Therapeutics’ filings with the Securities and Exchange Commission, including the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ending December 31, 2023 and its other documents subsequently filed with or furnished to the Securities and Exchange Commission, including its Form 10-Q for the quarter ended March 31, 2024. All forward-looking statements contained in this press release speak only as of the date on which they were made. Cara Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

 

Financial tables follow

 

 

 

 

 

 

CARA THERAPEUTICS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands)

(unaudited)

 

   March 31,   December 31, 
   2024   2023 
Assets          
Current assets:          
Cash and cash equivalents  $46,996   $51,775 
Marketable securities   22,777    48,983 
Accounts receivable, net - related party   1,718    2,765 
Inventory, net   2,741    2,821 
Income tax receivable   697    697 
Other receivables   506    555 
Prepaid expenses   5,790    8,154 
Restricted cash   -    408 
Total current assets   81,225    116,158 
Operating lease right-of-use assets   3,826    4,864 
Property and equipment, net   3,548    3,322 
Restricted cash, non-current   1,500    1,500 
Total assets  $90,099   $125,844 
           
Liabilities and stockholders’ equity          
Current liabilities:          
Accounts payable and accrued expenses  $14,875   $25,592 
Operating lease liability, current   220    - 
Total current liabilities   15,095    25,592 
           
Liability related to sales of future royalties and milestones, net   38,376    37,079 
Operating lease liability, non-current   6,825    6,088 
Total liabilities   60,296    68,759 
           
Commitments and contingencies   -    - 
           
Stockholders' equity:          
Preferred stock   -    - 
Common stock   54    54 
Additional paid-in capital   745,381    742,036 
Accumulated deficit   (715,441)   (684,745)
Accumulated other comprehensive loss   (191)   (260)
Total stockholders’ equity   29,803    57,085 
Total liabilities and stockholders’ equity  $90,099   $125,844 

 

 

 

 

 

 

CARA THERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(amounts in thousands, except share and per share data)

(unaudited)

 

   Three Months Ended
  March 31,		 
   2024   2023 
Revenue:          
Collaborative revenue  $788   $2,750 
Commercial supply revenue   640    3,191 
Royalty revenue   -    125 
Clinical compound revenue   84    99 
Other revenue   623    - 
Total revenue   2,135    6,165 
Operating expenses:          
Cost of goods sold   620    2,590 
Research and development   21,964    24,334 
General and administrative   6,816    6,891 
Restructuring   2,401    - 
Total operating expenses   31,801    33,815 
Operating loss   (29,666)   (27,650)
Other income, net   952    985 
Non-cash interest expense on liability related to sales of future royalties and milestones   (1,982)   - 
Net loss  $(30,696)  $(26,665)
           
Net loss per share:          
Basic and Diluted  $(0.56)  $(0.49)
           
Weighted average shares:          
Basic and Diluted   54,588,090    53,872,038 

 

MEDIA CONTACT:

Annie Spinetta

6 Degrees

973-768-2170

aspinetta@6degreespr.com

 

INVESTOR CONTACT:

Iris Francesconi, Ph.D.

Cara Therapeutics

203-406-3700

investor@caratherapeutics.com

 

 

 

 EX-101.SCH 3 cara-20240513.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 cara-20240513_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 cara-20240513_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm2414193d1_ex99-1img001.jpg GRAPHIC begin 644 tm2414193d1_ex99-1img001.jpg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end XML 8 R1.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Cover
May 13, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 13, 2024
Entity File Number 001-36279
Entity Registrant Name CARA THERAPEUTICS, INC.
Entity Central Index Key 0001346830
Entity Tax Identification Number 75-3175693
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 400 Atlantic Street
Entity Address, Address Line Two Suite 500
Entity Address, City or Town Stamford
Entity Address, State or Province CT
Entity Address, Postal Zip Code 06901
City Area Code 203
Local Phone Number 406-3700
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol CARA
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://caratherapeutics.com/role/Cover Cover Cover 1 false false All Reports Book All Reports cara-20240513.xsd cara-20240513_lab.xml cara-20240513_pre.xml tm2414193d1_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm2414193d1_8k.htm": { "nsprefix": "CARA", "nsuri": "http://caratherapeutics.com/20240513", "dts": { "schema": { "local": [ "cara-20240513.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "cara-20240513_lab.xml" ] }, "presentationLink": { "local": [ "cara-20240513_pre.xml" ] }, "inline": { "local": [ "tm2414193d1_8k.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://caratherapeutics.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-05-13", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2414193d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-05-13", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2414193d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001104659-24-060529-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-24-060529-xbrl.zip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

5-B3,?V=$&:KX&D+ZR!@(^PTF M;(]")-Z/B@C-'!\(\&-K(/'?46\\/!J1D(_GE'.7TA$!ZN55]D#L?V!B]^M\ M!>!OGMWUW5Y:X.QWB@#Q__E:\!^I18K /55,)O:2K@#LCXR!U,\PJ7L4HO*^ M$0F4]M84G/_@PSZ0AX1ZR'1,>.'1T![38=P5YE#D*#EGK4Q4[/]2HL#0=XRA MR%'2T!J)#0,?9$KM.1,<5?S64.0H"6B=R(:9WPC#S-K- 7S.TLF/!Z?[K(^M MH(Q1DDZ?*!2VY9,&8=S41HCOH264,4JN&1*'PGE@]2C"1R*AJX]T'0)]9 HE MC9)C!N6AH+Y7+"5J/69Q_:!Q; N%C9)9A@6BT'XDJU%B5;$I*R8'ZZ%[BT#9 MHZ25(+DH(1B)6*J%W'EW#L*'EHKWP MQ44>TMM+2RAOQ'2U6APFYWNI#>'_L47=G62U/90Y8N(:$MKT \8B[NZAA6\I MT8$)E"]*KEHIIVFD+L**$G_WW;> D5)0*O$-,SS5KJYC[D4P>>QQU90KBB9 MI$]4TP.O6U"LO:?^SM?@%6PHP^JAC(8Q?E/,6 \&,DTSL7E&XYD5\YA"\:*D M?T%Y#:,>2\YB9IB8?;)WB(H17LVYR@X*&279\PMKF/"]HB[2U-YVY^NXW(X# M=3>=^D;>D#V4.$JN5R\4E_Q(ZXRJE_*O* 6- DK:!Q7=]#A#X\P.>^MN;_+H M=LQX1IDC*RAKE)3/)ZIAMI_EHR)N[]YXG4XD]V\/J32$$D9)\ +2&H:\YT#23P@M>G]>_F6'[>K6Z6Y'T/[H1J[QQ0* M'&>+9$A>TZBSA!F:%"X-F2 BMBG5=E^;)SNO+P4- ,X>2J!HE,?[WRCG'X5< MBC$E6@J:%+?ZH2?\WB+0*"#.(=;(10G!5\DS2TGE"T&5YQSPF$*1(\X=>N3A MK+TL%C5OKSW%ZSM"Q'TEH. 1)Q'#8I'6IQGJ?&;/]#TQ9.-AB+^O!)0_XH1B M6"S:^GDUL!>>F0S/F1\80FDC+H6ME(8">9P2SJ\SS035P;'EP! *&7'-:Z4T M%,@W*54S.ZA]4')IYIN]G2'8G@)0Z(@K6X-2<>"O?NPC+_:_!P64A17LH=R1]U8Z1?:,/D[]^:NW?NGW)F1S=M"BQ[J M2T&C@)*N0D7C7%MW=O('+ZU[=E#>B(EIE3"&Y%Z[O,Y&\SM?X%'QH$RT%#@[F)$R Z;NT!][[:XAOWR[V3U1[Y'U!+ P04 M" !5@:U8^ QS",P1 #X7P $@ '1M,C0Q-#$Y,V0Q7SAK+FAT;>T<:W/: M2/*[?\4<=[G8508D\;#!-E<$XX1-#%YP-MG]XAJDP4PB)%D/&_;77_>,)"00 M8#O@=6XOM6M;FI[NGIY^SD.G_YE.3'+/7(_;UME;M:"\)6>YL>\[]6+QX>&A\% JV.YM4:W5:L4IPN0D4'V:":OEIH(_9A.:YY?G4TEG36]]7XL34&';HF3X'BFXA(J;B$&EJ->8TO%9-(,E[3$\A@N?"K7V_$<]QOJ1&>)8F)SU2;!Y2 M+Y:XP1;$'=&$!NBAE2) EXU6HJT6H34"#+S\+:5.##RBWE A@TIK/#.M4WF M94*+EA2X;@>6[\ZR.0X;4QT\UU]]30*UFOQE#Z=2E_IBYU&&!SW6OH-L3 MA"XK%;640QMCU&CL$?QWZG/?9(W3HOR]=SIA/B6(*,_N GY_EFO9EL\L/W\] M%(1:A5U&B//U'/D\N.#.-.ADP_X1TZ835R=28GI#.N?CC M1M%:-Y\';[3S]\WF%?S"89!\_I&=2]4;'.M-UAAOHC$^'EVY''=Z1N]*[8:! MDL$@X+_FA%D&_.]?F/3V9D1-CST!DY+ U+9@,F8M0.52LV,9;/J1S6X4<&FE M;?4=B/K\1KT)O8/$#Z^>@$*[&8RIR[P;[4;X0HG#$^^>@.8<.;D* M4966&%J%>V@;,^+Y,Y.=Y4:@>W6B*HY/KOD$(+KL@?3M";4.Y8M#H._R$:JX MP>^C;@;W')/.ZL2R+89M?%I'=64NV(!XX(;!+#0(? *H;C !/+I4]JG?1[_1 M]'HCU)"\4LF#%1%NG.4NJ.XK^ ^>+1@TT&*\GE*$7$-HPFDQA?E':)63M#)5 M)=>8ZTH6X6)RS,@&N#[F0C!FGFA'!UOW1.0$=H@(A_6Q\)YH=OG(4 I3S\B% MS3YXA[..R= CA&12F"4ISP[HRHH^4 %S#,)S)W&(A&P<)BX)8%B3Z'LU+?=>>N3Q[[(7@;.!,5S9MD3 M;FV@N5$>BT0ST$;-R>$OBC$TO;FE29,/?=YI$?HV]O;V3IW(14ZH>\NM.E%R MD DXC613Z'3+FYSN"8F1 *AR0E C\]3DM_!*!T-B;HP\$3#Z@;W#@A86.$2;:K\W8<<][C?T(4@[>YQK__J5:5$RFW\&=B",74&'8G.\^A M5A)SQ*&"+)X.8RZ'P"/"[G@JAXW/W&(I6WX;^YX56@6A*I5Q;0WEC MPO(HRM'T9I(XWM;@+GK]2R)5#=TOYFXUY4(DI_G\N:T'F-A@*7"CQXGS/(7^ ML]<=,.L7_;?RG0KHGIGA'"N=#PHH7@6N%U#+)[X-'76LR0D40;T^42O[Q@&Q1^1ZS+ I<+G/@6![ MJH^I!>ZNJ?O8K-9*Y?\%\6.ZA>/I,\=V?;(?/3,*P95Y/F'W $E/!\^R6;D$LI9CD_]N@'8)P [-NAL M!OPR:\&F:EDVE6(NU[BD,YCY0X)$_EHK>QE?MSAW[\*YDT55G]UR#]>J?*QG M5TS=I]_^F/Q6Z_#6\;/=G:HL%W1IVKD&+GF0ZP_M?O.J_?FZTQH\1RF8S%E$ ["]3T"S@+,Q3W8$DL+KL"G0Y,!9Z8) M8]=Q,3D' L5GAQI&]/QDDJG$$E-JWXV0W#/7YSHU(ZE CAG6)J>^$0$MBRW& M6=+>9*I?,Z5^'4NW77 T8I%TX(.!MN3B8,LV5FACW[H8J!?LCCG?GNM(I#1 M]1GB;Z?$?\%-!GP.F9LMZ^#C[(']6NHXP=.<=DJ4VK(HYW1QI4+-EZK:4>UU M"ZZ:$MPUG7;"]11=Z,,Z*;:;Y>[%A^/SECIZOA1+RU)2\P>K1'(K7G-0R\TQ^0]L0Q[1ES=SWTM 61KEV82^#)UI$E MJ2V]>U66>BJ]R*;HWC0,EWE>^.L3MYB:[2'+]]J[NX?SX?OSH^=[R(PM@PP& M9=BG195F6-\A2RY9E=SRYGU3IA_&P^GQ9 M5AXC2RW7& 0Q^70"^:BQ0FJ'2VM3[:P!B7#9TXJ9E/"/5PH_Q0&DVE7@=-LIX;I)V _YP/K9 M<6'^N4--PJ8,)I_?8UD-@9=Y!R\YTYE\@H@(RNA@:W'_B1SO>( _D$B 'N*B M@W66J^36D9BOYKSUP&Q,YHQMBQ%+9)6'F%V; =9K!&ID"D@-1L"0]E?56>@N MFP"YVG8^NZI^_&WP>]6L/-]V4BN&29JYAJ:L*I\.EOQSQ/4G&\1XA0-?5Q#^ M\G5:._JEK/[>>GY9K:46U!;I8I93S9>.-@3F6'LBG2B*A:;&MI?43#;R=[JX M+0FTQDS_3J!V)-2!4 4>!^O)H3TE0V;:#X2/1.,%A#9RG/](1MQ$A>0>:*?/ M+(,9N#W@\4E@^M1B=N"9,^)!8>"-9J)GV,$> E59+]@296)Q, \+J'6+&H; MV280QWX8/CG6'RRTJ#3OS8$AF^!!U7O+)ZOVA$( M/*0+XTD2)DYB[PQ/ 9"R5@G5W$_OF>%6V;YZ1%H7?:*5E ( +D34K3F8GV.! M_$6TN1)J\\ VN0X38=U>@M\#YV=FJS*M_OJGWM4KTUYM%ZJ<6N]=YND%]'A. M%'1&4EU68K5,\ZJ6T./4AF^LQ66E("'_K\@OILA7+D/?ARE_-VPLH-A#/ZPGJ&SVU6C;RVO[PX'%J+F'_ MK^@[5_1VMJ)W/"]@[D9U_R6H.NS;U<#^8NQ"WI]"66+^_KCU/Z M$/:%E'Z[54\H+@AX\Q1,5B+,A5K&R3KS)+Q!6)F ,+9=8KR8<//-^* M?^.U#3!.4RPN7N,E)<&<.):ECXEN4L]+[49D&-+R8>#$$,+&D.M5S2O/"D>" MKVU! C! ER*L&,!@-AG:YLI-_A<85%EYF6G%0TZI66614P*[?!AS>#,WWL7) M?NZJ[ ^**&R7XU]JW8K0YE'Q/*ICI#>;J=I0F$)V%&S.9I5ORA_FM]+3-C92 ML2ZUS[5(%_A9;:'TL1E>?_?EY)MA>T-THY5I^K M'++@H53U+GIW3SL7M+@UAWXD:U=..\K2[B1?N08>>NY2SZ!W4LO))76_,Y]\ M^M1:-Q7_(PO&'T' M?XS9J(.KO=0C!AMQ2QX)E>MD2B5*M186R>1Y\A+9QR$>G8BUL@B8B\.D#AXF MQ;-0,J75AGDM U?6(?48*::W\WX)M(7=)'T_BJY0 <&MG*OV"KGOKDI+GY2. MZ+\7Y%N2^HH]]]:7#Q??!OS6UG91H&7L]V8R]\3:;"MS*'Z6U(KS(N8[6F.0 MN.486_=>PKKYTI;-&&R7F5 A@>U:MJB7 H\)** 9;@SA]QRXJ*'DY52<+4'+ MG"'Q!PZD41\M& ZTN.R>>] // *U=$[-/:J+#Q\@,'Y,PZ"NX?>^RE''M4M[%?,*]RTUY1^)>YI;O76Y# M3HC^!*#O EQD :2"EDBWED>],J':>)FU*NYP+M_'33N+\.;N$G67T>_Y(0.S M PX=P7&28G7%-#Z18E+T6Y7Z3[3XJ5;>I-4TNGS;\=F$: 5%*ZPLV$,4QZM0 M])D7F+XX$=1SF!NNX8$[!*F'GI*T;/#!0GU3"*- M+IT=DA9U*5XWC+_K(/OH[/_]SV--4T["0"Z>U).#/8[+KP:A$#;P M5)4+08M"H**6!9%%%V<90+1QR $ *6P,5?+\@NOYY"X05Y6(#&R0\.MC2;^D M2@X+\K$)XZ-Y=&)A>P49S4.6_/3[)@JMZ=C/N2^ M)%2K%539'="V M?%5=[P?B* XWD-"8B'-A"I.+$1G=9GQAZD[_$W.&)$265] MG0$+BR]NQ1^)2L@RF0VD!Y,\2;4DQ,,];TQ-4R0Q0P;U".1&8F+@(3?B)C-$ MDHGH'=MCP@K#9"/4T>-'%QD)-8T ]@ @TM7X&L<#I$'$"X;?@$ZD(R:G0VY* M[((>A2 B^3C$)3,BA\&71Y&<=I*:=FX!A#QVLX*>5 2S1X>8DT)6 M:(8G)G$PM^'9H-3E%&("*P$&)RB8O$"'Q#,3,/5[6" MHJX.5ZM0'(8LA*@Y0V1\>^1G$&JV+0^]]XV!=E*]5 M 2:2!,DZ9/KS2V.3DJ6<<-=^OJJ=,T]WN2-ONRVD/7L_R/7:,\?K8$.EWDP= M#R6?4B(_H.5/M+):!F]HJ#=L6JOEU<+8G\23AZN6>4B^7*K#)#(IP%P#(]AI MD<;2VP+**Y&T],,\R1!18RDABVG*P3YVM*I23G+:L@%8U"42.QXI16[PG#L0 M%AZ:D7T9[9$/"!,=\;U(@A^,/,CT(:\P:=E7CQY=U&3A)3A/"'["I4Z:+F0X>O250)10U\9Q:ZD" M,^J%+7^O GAG5\$&G??=YO7GOOQ6TY9U?\OHKE)9/BY)W@7<#9.,Q^7AAWL9 M:YE&8,Z(3@-R R:+#E=RN&#%+M$:;2B$@DO"$ )J4!)M4" M'0W\L>U"D##^'CEF9L",K\)H\C-&2Q\L">MX\=6288,L?*]L6U>+DFS\R,V> M=#)74=9_-"%Y,F[8>#>K;SJTL?'@Q9%$5?2*I/][LTLNF[]WF_WSK0HK\UU_ M1L7"C$7Q#N8N*;7&G(T22UL]<>/-W2W1_:OXKMV<,A8MS?D61,C(BG-OK]!9 MXM>;ZEG)V^OT[9O3I%)FFD0^4<^/*; MX/[$;/P74$L#!!0 ( %6!K5A4TM4=^QP ,D6 0 6 =&TR-#$T,3DS M9#%?97@Y.2TQ+FAT;>T]:7/B2++?'<%_J.?H[>>.$)C;N-OC6'QTMV/<-FOH MF=U/+PJI@!H+2:.2[&9__2=69E99]];/V[/,P=G MWZ_K5_ OP?^=M6Y:M]?G9\?J7_CU./CY[.+^ZC^DV?K/[?5OAQW;\CZ30M[Q M2(OWF2!W[)D\V'UJ:>H+C329RSN'\"*\VAA[KSSKO2^D3]TNMSX3G"+_A7CL MEY>E)N_"5SJS/.8>GI]]O;]KQ4?."OY?II9U>/[1:@OGR]DQ/@3[:6QB)2[O M]KQ9"SF[.+_^U>-M[I'3TUSA[/CB5=:6'BA%*TD,GWSJ"YF7M,(ILY[MR&FC M+]JVY]E]^1U,>O/C&VD^7,)D_6*Y4"ZTCJ MMZW?#H?P>"\HF46YE]2EI-5C+G68[W%=9 X>F&.[GB!?N2L\\B^?NC 4*>:+ M9?C*HI;.J4D>F/!-3R"QS]K)W)@.=C*.I#4,N11P;F =!A6]+Z1E.R:W6.: M=3I@Q@3LG17>,3V^0ZT!,1DUN-6%MRS8G>AS7=[GG W0\VZ!(99;M6SJ@OQ,Q7DAN M2(&V _M"RH+O>Z"J3%170(FV*^?K( -G#OX..!AH!T;Z05V]IV!0*BB(Y=X' M]7PTC;]]^\N][[[ A9F#D UU8'F)[Y ?N5 ?F1 2[3W /V)3Z#UF^":3*'EF M,;X%- *^D/OADQ0A9%X)DCD8%2%#_L8!IR$S 'U3"T$),,9%A["$#Q[/*B[B M>HPE0XY >Z*F#TP %)TDT8A]A@P%(_9M [4/ _L\*T 2N"S27TC2H8[+'#QSKP<, MET,U#%I;*4]FN;9I FT7"^6A/D1&5J)3+"PQR0R!F3F8+#%SXW $Y0!"X9FY M@:@!.\ #*2KA-11).L,-P>, $\,&GGWFIH3G$PA7\L@& 1XNR\EBT8$;$J^ M:)H#)4$05<&>^HZI9!,*',",E!DQE)6&MN$H1D/TA=;.<"<7^,@0,CA/3&D( MSS=@&>'OQ9RT[,T(YB/PC4R):!7R=0*J8Y..OAU.P2TPJZD+ M$A9>JJ;-%'DUKKZQXI:9U.02=B&_]&P!8,X<4/+$7<\', ++6:!1?C!0B_@D MJ+1KP 9X;AKI )_ZKC).X75F(E)">W6HI8&J%<\AN=H.4!Z0%CX&:AA)T>!" M]X62+#']BRB#V4*:X-Z%@\1'8XXNT6N [R4TB4'Z9 ZDZ&;FQP+#V;%BT0(M@R!\!]"(3 M!&86W&,:.?MY_OS\G$,39\3 1U\=OSS/&UDN!:W]R\?A%AG,(>R+:!W^?O] M0_/G'_7,P8WU5P#5G[EF+KT:^#6!=&/%Q&*@4)1C+CDW@-U9\V?C_*/+NK!H M_$B.1CCC$W!2"-HNLZ0V-8#%/% )IO(4J0,B_A<'?F4@(3\4Q&WUV85'\D!5BAL$UNP#H:H^,% M(=)A..WL&.:<,'T;C)C';)N!P0)K=.2:XTNJ3E@1+G/1*6. .4;(*&!L(&;X MAD/0;X,EEI*:?_9LD!0@+5!3][CCH+0J% K:23$/=@TU ZN#F@.!#K%$ER"& M,F42 C>RX'=#RHR"%*W-6>NXM\;">9F#H>78M:[JC?HG N8CMY77DY#E:.MS\(G GNL@\.4<^%KPEI9\!0PT M](]XO^V[0FH5U_:[RBFX;CY###AV)U;+BC#_E<^30VG**^L?&B4#/MLU"> EXEP;Q7/)[=G#\H+T1\QM/* MS$%+1H)"UT2BKY@KC/@V'ZJY8O1%%('LN8R1/DS0$],/M.3["'$-><]1IP3F M($>"50QY$YTET)(86P&D?TX'@EKUB]MK]NH7UW=W'W[[3!_*/]N-NJ7 MX=]_WERUOO]V",+J'X?++G.68=MZ"$=^8JZ,@(9HAQL=14^\8@RG&,& M9*?U_D$-X?C3-VUYL&9?-6_('!^X9 M>O%3G76MQU\!34:E"8X9WDO$66\@"7#J"W^/6 _X'.6+/DGN6'&')Z@HL M68HI%\F2_3YSI;$M?,>11EN"+:>SSF(+@:$BOGR9Q_9LLV>;M+ -'NYXF$@R M@3-<>T!-;P"*0X86@'JI:RF'!NRKOWQ+*1AY(LA^J7,$R4V++67(>L>_4\?U MGS@-SHUH%UA'32TG&?(7<@MPD<]%C^-Q:BR32Y!+.T=N/2.G+;@.-QI26YR! MPW@[GC!CY-8(]B#/J!=91L.'L6EPBMRDF($4@D%!X?OEP[^#PS$%F^\PFVYK MY#;7R,FWOC/ 6T]'4^,AP"&>(5O,71 U-W^H4:6GA+" N4D]7(XF)Y.FMB'/ MU2W;RJ+?*WUH5WD ECU&8 JR"\K6>=%02J7 W(IO=FD+F='QS;8-0'O3QO@\ M^FGA#UW\09&J=-5 AHP;N-7UNFK D#'Q,ET[3XY4*D4=5[/OV_46# &/H,X< M7 TS7,G1@SQZYQ'OPM')-:D@BIEM;9AL,WP919-&):3SPG/UA^S;8HQ-EP( M#$##D#8.!M0&F@L3DB0YAI2G _EC+JY+ 63J+Y5V&TBI\"E+)OKI+'P$X85# MB6#IX=?"UE4R8)09@PD6 #EN^529D4'R( 6CA.M!I@;WN)I7I2#BE#W7MN#W M1VY8;("CX%;#;"!8LG3@,-4((-D1S,/T'&Z%$(EQEDQE3*1LR/2.8+0-<,[Z M#\#F.'@M[@]>]P>O.W?P.J<*^":S2TRE >I&GUM<>$'\Z>B;E*SUF!) '4"" MK\>4 !-")7N!;.F &,'CD0_56'QK;KT0G'*-*(9J[I3,H1;>MS+W7%_W M-X M3&_'?TQH[UQY6>4=\U?&HY1(1:R+9R&@@FT\>OLO#3/P8CF"<>5GNX\POXYC M&;XRV )=^-).#Q#B8'?A9OE M0OAH[N(1W33[>734Q:3:6.C!F@JJ8%B4+7NY,DMN'18 MT=*CP.&R],UWL32,^);4:UR64$CJDW&RL2P7Y?R%F?)9H,2^R#J7- M9&TIUV6)&\B-CH^.ZW!J//K&:CF=.Y*EAGDGCDE1(<,[LB"#W,?6._84L*2/ MT-.9ZU$9ZT5&'3,1\$F,!8?E'[!=#+W"XW>-=\XK]386#J'(BJH^AS5:EV&- M5B.L/P6(A76KC5C=ZGOFK["""2,DJE@*W(K7+7!3VFAB17'F $N*510K5D6, M+H_+!5.5:<^VK(A"U@W+N$;KMJ(JK>CWP!Y'1L<]@$76QGHR'Z5#&_9C:,AU M.FO;60POJ4H[,/)JV6?&'J/IY,*'M7!'2*X0HM053S1D0I1B!$T&&8*PF,U[ -QS@*%:!B$4A MNND;L/*1TLCGGBTK[EP@";L/ZS!014@_',6[C!JZ?4&.\%PR<]#ODHN;*XU( M2SWX7(Q]#N@#__BT? 7D>\5]O,Y2QE2&/+HH5Y(7F3*&[<+G F*:<>F@C4W>.1/!%9-I=)B1%_6JP;Q@V<;\T0Y ()88)BX M&)8([!4!M+L)>MU*++NTCV7O8]D[%\M>U&Y.M/9YSX9P AAJ81Q+)-;:U8@L MV]0H)WO)1.6J8&8$RY*S6'A:F3KCP>>IC/I$GDO]/J0GG<00PL;FX7=&((8W$2[8$JOA^F] MB'))%@4O0]@AXK$MCD5 @<2P+@WH,;0KD/ @"OVD\LIPVI\6Q_4TP3Q%3KK^ MJ?*,8"R/8TL-=5"OVSY86VBB+.KF :F,X7[6$3PLC!H2DA+_JD=0C\$<05&C MPMKHGG%K(-"R)M!!%G'1N]/17<#BH)UP9O_)D-01- ML/#X0880)3NYK L01!X"DI:UP!A##>2B1WK8W,R5PJU#,<**/WS\V[>]+YU1 MX$L75LVJ?I?L'(B1/J.6# QUE$1NN/P)&_ TAT'56_BGJYCU 0W6G.C28,G_HW\>_ D#HS+6"/-+,P7CKA3"&&A[ZL"Z*#FP) M)OQVGPL9B9$\.&S&DGQ6B4^0P%KX(_R-*H.8U+= :\(/D9#W>%\2;2#A@ZY$ M4JRHWDW108Y!/1IV08JU#)JV!YE!%71/BW23"@IK8_UDAEH)UC'U%;G0^)%8 M;,>XO%C"V_!\+-(%B64&(-'A78Z=3L86E3F8^TTTE=J8G0M:#XC74OD6 =%Y M0U&,9$N1+C!1%\D,PP**2G!G$^T-39&J;!J%NP2U\.Q%9[!#$*HS K7=R*(! MI@8C4$)$^)@8**9,$BJ$,/MRI-7/!!A@%D "?&.-2B)XR6,.U[>>Z2!'+IA. M?<'4>F*<@1P--/Y7V$V1BT=%Z-@74YXZ(']J: #Z0XH!94@'00L^%!W,#3)6 M%'%BYRT@=!0U&(1UT: UN;)LY *F; M)P;[)AT.%-P5PT/,F)C!C5W_TGO4ZDIX!:P=IP9\(^B2] "K(%]AY[8KHK:/ M+S9 RAS4+6R*R4\"%JJ'S10S6=_C]ABP*CL&(I33BY_EHOER)TJ(&7K M?C^P_]M"ABH\A#@W0]L)1N[X(.1$#P5^D'RXV.9QNI$%_RM:\.PNIZ1NFN.8 MS1R(">J(3-9&PF'T$6"&_L;05$9&C\[/X9N!REGI4S3?D@:PM L]^LA4PGO; M#/2*A(@O>RLEF$"V$>V@YZ.Z?@5JT-8!=@A6G;L ?'@!>"+XC?T"W0BN1MBI MX:5EHM1'WPAVA9[ WSZV>4!>,.GS*X;,7B/(\G*Y>71T+0]5!8IZ-(MW)&I8 MWD<-]U'#-$4-M\[PV/^^_E GK>_7#_7&]<_6S64S[ ]^=YE[T4M+Q>+O[ZZN M[YK75P0^->]O;Z[J+?CCHGY;O[N\)LWOU]>M9KIW<215K>T+T/[B4XK7Z5L4 M;! PS<<7.;K0B#\2S#9?+6PH%96XE9T"' &K"#^AXRK+3[%:=GX8'$HQ^$(5 MK +%82@MA\6H4YEZM&9U[+&@\O2984=Z'-TT1MX<3G-YC_N_^^VP>#C_6)/O M%CR^(9IXV?Y(%#K/#5?T#-))*1O<<>G5B.<+2<:L MW6[[J)@O:\5232M6*I]F$]C$]=2QH[Z8L9,IX)XV33*6.2>>)UP:M<2;"TSY MUC>V$@7]J4X]EMGV99#)*N]CP$JGG8;RSFYLTP+(H08&G+(X,[;Z*&"OC\CV M.BG_8X+\G4!LTS*ZI[04*22'?1E1T]^;M)P/TZ;-SWH_0%VYJIV>5N=?_&*$ M,Y\M'\TVFX07'' ND"T^;OX?$V%9*6@G)Y4UP&$KDG8*?\R!_Q^3BA;2*ZV* M14#3R0Z*X7)-.ZW--@13*8;G6&5=EVD?LD*4@=@%>E/5C-FH/@53M ?I11#( MAT)M!PD/&*HZ4>YMVWIK[RIE,NL^:&(4$E2*;;!*/N%S[ !%52I;U8(;%5D-ESEX M_VC8IR/%6-!.3O,[2%TUK5"9'=A^4Q+K8;14?B78+QQ\W:G2QFU::=U$K@P.VBC5?6:M6M:N$-6WG8#\93:?9XNN&H7L^ICH&4 MM$IY%\-J):U4+.Z62!LS^%1U9Z ]=]?2*6B5_)8\DIV'2VILP#4HY(DP+>8J M %75=&2Y,^%5APVP=9K7\J>G*2+CU$ &Y)]6*Z?2-W\)RJE4>OLDF51)._G% M] Q$M<+;H$]H6/(EF_/WX&'F1C5R:$RF^6QV3W?;EDTOY?:90PK;)_B]T8VE MU^N-,DL<.I!I3+([JZZ[/GN] X^)>6DS+8^R5IN<K"=1;ZW9 M>9.R""I:Y72B"[WL^E+L6X^'"Z/NW1K9>0^[6-S[U^L_=4J-;ZTGS8#T*LM" M!?SD79+)J^9W[X9@WGO2.[6Q]%JCMZM<$I+VHYJ:5CI9[['@SLG&THF6/YD8 M9TVM;-R(T?HNCH:J6FU;"1DIATN^MC/I06_";*WFM6*R$G OFD=@5--.*F]+ M-._-UIW:6 IDFNSC%]P^']P!CPJ<67JJY=N64G!3O:>]Q-E+G#<@<9JQ\^3_ M#4Z2]\> ;W1C*7- &R[K,!>[H\JLA?0"?Z^_WE(0[U+>&9)VFEJYGFS'_;W) M\$FMK[="!@2\B"VKL2$\Y486;WZE#O>HF5[B/2E7M%)MOE=D/%1M5;6@.'72<>? MTBF)8W0;7G;5=US6P\MYGQ@Q;;&!(H.TA/V/"J)MG,C"%PB]6) M65+;9*!U'K-L*.T\U0Q3/-5J^55[ONWYYF4OX$3+U]:J>M*06I\XFMQDZ4:Z MZ[ MZ U"E?T-0INY0>B-7Z.SW"5$J;K^=/M W,V[B)HM^.?']5VK2>Z_DOL&;*YU M P^D>S]'M*]JO.*W$T77Y(D>WOPH;UL%CUO]A9>@[J\O&C,/=NGZHB\D#--$ M.F2J'1O=YE)=\=Z?V5JSU7,9(S]@L)X@UWCWY=G%PSE1RU+_??E:I F[FN=N MF27=DM1A:-6;F69C:-(-0VL!^F[ )A&.>%V"7%>8:3R&>U)!^#[@=:T^VZ>? MO-&-;236=XJZBL_'=OI%K94Z2R?OKN%/FC>R^ MJ)U4$I'VY?>_]0#[=(J-KI$7ON.8@VE4FQX94BWO8FOHDK;^ 8+:Q;2\PLHE:>D562:W.3:U\W+)M<37BRTRF MM? ^CGGH:Q%O[BV<2U>7]0*7)K+=@E]"K:P#>BF4RLJI5F?1J9?$1:U0VL7N M^56MD,[[VY8FJ&%;@;!]VSY@\T8WED*A%7J_PL..+%W;-@3*=B.]F*ANJS_: MAN5Q9>6;GM(BMP*WEPF&9SOR*-( ?6C:\@:&%..@H)VN?"%&*C=6UDJEM-_T ML32A?6,6:$A3=3HU^N 4"T]%GM.+D:I6*^SBE3*PKS<2O5O ^94W??BZY[OP MVSMSWHI:.9] Z-[]W;N_\S%0W">V$X[,.Z.$4D&K[9EI-1"60'$F_/NM<]0& MG?Z5B^0VJN^/BJ=:M;J,)3.QSBTMFSK1JLE3[_DWE2+I/%*U&<;QN;RS/>7] M54\KJUX8E\I=3:Z^>D."ZD5]'Y#9'?8[I:('E.8Q%\SG4.43VQKV15VF*? [ MTW='!>VTEN"#9?7=+)F[:]![+Z:W+&V;9DK<,6\>(V+*J&^Y%O*HE->JR3ZP M4Z"W$?YY^S L5L' FVEQ+PS#UPWRC')$VFV$_2%:JN3ORV)U6&6U/Y9]HQO; MMD4]2E@75'!=6KU7W/3!/-XT])>ZK>THGZNDTNU?=C?E9;+XMN7O[_7:[FUL MFQ;1G[)4#3QQ"E-B\P"IT/:)1F]U8RGR4;>LW)9'1*6L56HU+;]R6DXJ-U?2 M:B?83G-M%].\V5XU*S7FV-"L9Q?G/ZZO;NK8K:)5OVQ]?K$AQ8864;NZ#".^ZYTX1<1U>E+*GE1KV6+A)+_9;?[E"X]W!C/I[NI22V="MRVN MD48O=Y5[[65<4I>25@_L0H?Y8$*LG2%G+:"8+V7+^6JV=))?.Y?,P1#<>L*S M)_>?.@#"B\%A>KJII:RUV?'%_=5_SO'# M]]:/V_/_!U!+ 0(4 Q0 ( %6!K5B%'@>5, , /L+ 1 M " 0 !C87)A+3(P,C0P-3$S+GAS9%!+ 0(4 Q0 ( %6!K5@M$PV) M_0H ("& 5 " 5\# !C87)A+3(P,C0P-3$S7VQA8BYX M;6Q02P$"% ,4 " !5@:U8LNJ7;5P' #E5P %0 @ &/ M#@ 8V%R82TR,#(T,#4Q,U]P&UL4$L! A0#% @ 58&M6/@,#DY+3$N:'1M4$L%!@ % 4 20$ $E% $! end XML 18 tm2414193d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001346830 2024-05-13 2024-05-13 iso4217:USD shares iso4217:USD shares false 0001346830 8-K 2024-05-13 CARA THERAPEUTICS, INC. DE 001-36279 75-3175693 400 Atlantic Street Suite 500 Stamford CT 06901 203 406-3700 false false false false Common Stock, par value $0.001 per share CARA NASDAQ false